Compare LMNR & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMNR | MDWD |
|---|---|---|
| Founded | 1893 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.6M | 238.5M |
| IPO Year | N/A | 2014 |
| Metric | LMNR | MDWD |
|---|---|---|
| Price | $13.64 | $16.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $20.00 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 114.4K | 88.6K |
| Earning Date | 12-23-2025 | 11-20-2025 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $159,723,000.00 | $20,932,000.00 |
| Revenue This Year | N/A | $15.89 |
| Revenue Next Year | $17.27 | $25.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.15 |
| 52 Week Low | $12.20 | $14.14 |
| 52 Week High | $23.98 | $22.51 |
| Indicator | LMNR | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 53.07 | 31.16 |
| Support Level | $12.51 | $18.55 |
| Resistance Level | $13.98 | $19.70 |
| Average True Range (ATR) | 0.51 | 0.73 |
| MACD | 0.07 | -0.21 |
| Stochastic Oscillator | 62.19 | 5.92 |
Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.